Research programme: anti-CD160 antibody - ElsaLys Biotech

Drug Profile

Research programme: anti-CD160 antibody - ElsaLys Biotech

Alternative Names: ELB 011; ELB-012; ELB-021

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator MABLife
  • Developer ElsaLys Biotech; INSERM
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action CD antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Diabetic retinopathy; Glaucoma; Solid tumours

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top